Background: Fractional exhaled nitric oxide (FeNO) is a biomarker of airway inflammation associated with airway hyper-responsiveness and type-2 inflammation. Its role in the management of severe asthmatic patients undergoing biologic treatment, as well as FeNO dynamics during biologic treatment, is largely unexplored. Purpose: The aim was to evaluate published data contributing to the following areas: (1) FeNO as a predictive biomarker of response to biologic treatment; (2) the influence of biologic treatment in FeNO values; (3) FeNO as a biomarker for the prediction of exacerbations in patients treated with biologics. Methods: The systematic search was conducted on the Medline database through the Pubmed search engine, including all studies from 2009 to the present. Results: Higher baseline values of FeNO are associated with better clinical control in patients treated with omalizumab, dupilumab, and tezepelumab. FeNO dynamics during biologic treatment highlights a clear reduction in FeNO values in patients treated with anti-IL4/13 and anti-IL13, as well as in patients treated with tezepelumab. During the treatment, FeNO may help to predict clinical worsening and to differentiate eosinophilic from non-eosinophilic exacerbations. Conclusions: Higher baseline FeNO levels appear to be associated with a greater benefit in terms of clinical control and reduction of exacerbation rate, while FeNO dynamics during biologic treatment remains a largely unexplored issue since few studies have investigated it as a primary outcome. FeNO remains detectable during biologic treatment, but its potential utility as a biomarker of clinical control is still unclear and represents an interesting research area to be developed.
Introduction: Sarcoidosis is a systemic granulomatous disorder classified among interstitial lung diseases (ILDs). While the lungs and intrathoracic lymph nodes are most affected, the disease can involve multiple organs. The heterogeneity of clinical presentation arises from complex interactions between environmental exposures and immune responses in genetically susceptible individuals. Sex-dependent genetic variations are associated with differences in phenotype and organ localization. Gender-related factors also influence the impact of sarcoidosis on quality of life and health perception, contributing to variability in disease burden and outcomes. Aim of the study: to provide an overview of sex- and gender-related differences in sarcoidosis, focusing on pathophysiological and clinical implications. Material and Methods: The systematic search was conducted on Medline database through Pubmed search engine. We included all clinical studies from 1992 to the present, and imposed language restrictions, accepting only English publications. Case reports, reviews, and pre-print studies were excluded. Results: A total of 35 studies were included. Sex differences significantly influenced both age of onset and clinical presentation of the disease. Women received a diagnosis of sarcoidosis at an older age and exhibited more frequently extrapulmonary localizations, with predominant involvement of the eyes, skin, and extra-thoracic lymph nodes. In contrast, men more commonly presented with limited pulmonary forms. Löfgren syndrome was more prevalent among women and appeared to be associated with sex-specific genetic variations, particularly within the MHC region. Gender differences also impacted quality of life and disease perception: women reported a lower quality of life and were more susceptible to anxiety and depression throughout the disease course. Conclusions: This report confirms that clinical presentation of sarcoidosis is significantly influenced by sex and gender. The identification of sex- and gender-specific clinical patterns supports a personalized medicine framework, in which diagnostic assessment, monitoring strategies, and therapeutic approaches may be tailored according to individual biological and gender-related characteristics.
Pulmonary fibrosis is a chronic respiratory disorder characterised by an overproduction and aberrant deposition of fibrotic tissue in the lungs. This narrative review focuses on the pivotal role played by epithelial alarmins, primarily thymic stromal lymphopoietin, interleukin (IL)-25 and IL-33, in the pathogenesis of idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease. It considers their function as damage-associated molecular patterns and the attraction of both innate and adaptive immune cells that these patterns elicit, thereby playing a significant role in the immune response to fibrosis. Epithelial alarmins play a dynamic role in regulating fibroblast–macrophage interactions during lung injury and this process influences macrophage polarisation and drives the epithelial–mesenchymal transition. It is evident that these epithelial alarmins play a key role in activating the type 2 immune network and, given the established importance of type 2 inflammatory responses in pulmonary fibrosis, there is significant interest in the study of epithelial alarmins and their contribution to profibrotic type 2 immune responses. A deeper understanding of this area could result in the conceptualisation of new targeted therapies.
The prevalence of interstitial lung disease (ILD) in ANCA associated vasculitis (AAV) ranges from 13 % to 45 %, and both its definition and management represent a quandary. The occurrence of lung fibrosis and ANCA positivity, particularly in subjects without any other evidence of vasculitis, is far from being clearly interpreted, as well as its proper therapeutic management. In this regard, aim of this study is to assess whether Rituximab (RTX) in association with a low dosage of glucocorticoids (GCs), could be effective also in the treatment of AAV-ILD. We prospectively included all patients referred to our multidisciplinary "Vasculitis with lung involvement clinic" from January 2022 to March 2023 with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), ANCA positivity and ILD. All patients were concomitantly evaluated by a rheumatologist and a pneumologist experienced in vasculitis and autoimmune-associated ILD. High resolution computed tomography (HRCT) of the chest was performed at baseline and then after 12 months, while lung function test (LFT), including diffusion lung capacity for CO (DLCO) assessment, at baseline and after 6 and 12 months. For induction of remission, patients were treated with RTX, administered with the two-dose protocol (1000 mg at baseline and after 14 days) approved for rheumatoid arthritis, followed by 500 mg every 6 months. GCs were prescribed and then tapered according to PEXIVAS trial. Eight patients, 3 affected by GPA and 5 by MPA, were included. All but one displayed positivity for anti-MPO and 3 of them did not have any extra-pulmonary sign of vasculitis. At baseline, LFT evidenced a restrictive pattern (mean FVC 83 %) associated with a moderate impairment of diffusion capacity (mean DLCO 54 %). After 6 and 12 months, a stabilization of LFT findings was evidenced, while no sign of progression of ILD was assessed at CT scan. No patient suffered from severe AE, except one who had bacterial pneumonia. All patients but three discontinued GCs. Ours represents the first prospective study specifically designed to evaluate the efficacy of RTX in AAV-ILD. Our findings have displayed that RTX, prescribed in association with a short course of GCs, is able to stabilize imaging features and respiratory functional parameters.
Interleukin-33 (IL-33) is a pleiotropic, chromatin-binding cytokine primarily expressed by non-hematopoietic cells, including endothelial cells, fibroblasts and bronchial epithelial cells. It participates in various respiratory diseases, such as acute and chronic inflammatory diseases, viral infections, lung cancer and COPD, and is known to mediate asthma and allergic conditions. IL-33 plays a dual and context-dependent role, contributing to tissue homeostasis and immune regulation under physiological conditions, while promoting inflammation and fibrosis in pathological contexts. Its signalling is mediated by the ST2 receptor, which exists in two forms: the membrane-bound ST2L that activates immune responses, and the soluble decoy receptor sST2 that negatively regulates IL-33 activity. Over the past decade, medical research has cast a spotlight on the widespread contribution of IL-33 biology not only to inflammation but also to the development of fibrosis and lung transplant rejection. A comprehensive overview of the interactions between rejection following lung transplant and IL-33 signalling is lacking. In this review, we summarize the most recent literature regarding the IL-33 in relation to chronic lung allograft dysfunction (CLAD) and acute rejection. We also discuss the potential contribution of microbial and environmental stimuli in shaping IL-33-driven type 2 and autophagic responses in the lung transplant microenvironment. Recent findings regarding therapeutic implications of IL-33 were also reported.